Prognostic Value of Leucocyte to High-Density Lipoprotein-Cholesterol Ratios in COVID-19 Patients and the Diabetes Subgroup

BackgroundBlood parameters, such as neutrophil-to-lymphocyte ratio, have been identified as reliable inflammatory markers with diagnostic and predictive value for the coronavirus disease 2019 (COVID-19). However, novel hematological parameters derived from high-density lipoprotein-cholesterol (HDL-C...

Full description

Bibliographic Details
Main Authors: Yuxiu Wang, Jiaoyue Zhang, Huiqing Li, Wen Kong, Juan Zheng, Yan Li, Qi Wei, Qin Li, Li Yang, Ying Xu, Li Li, Hanyu Wang, Hui Sun, Wenfang Xia, Geng Liu, Xueyu Zhong, Kangli Qiu, Han Wang, Hua Liu, Xiaoli Song, Si Xiong, Yumei Liu, Zhenhai Cui, Lulu Chen, Tianshu Zeng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.727419/full
id doaj-1429f2d6136f433b88ad7a0462800415
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Yuxiu Wang
Yuxiu Wang
Jiaoyue Zhang
Jiaoyue Zhang
Huiqing Li
Huiqing Li
Wen Kong
Wen Kong
Juan Zheng
Juan Zheng
Yan Li
Qi Wei
Qin Li
Li Yang
Ying Xu
Li Li
Hanyu Wang
Hanyu Wang
Hui Sun
Hui Sun
Wenfang Xia
Wenfang Xia
Geng Liu
Geng Liu
Xueyu Zhong
Xueyu Zhong
Kangli Qiu
Kangli Qiu
Han Wang
Han Wang
Hua Liu
Hua Liu
Xiaoli Song
Xiaoli Song
Si Xiong
Yumei Liu
Zhenhai Cui
Zhenhai Cui
Lulu Chen
Lulu Chen
Tianshu Zeng
Tianshu Zeng
spellingShingle Yuxiu Wang
Yuxiu Wang
Jiaoyue Zhang
Jiaoyue Zhang
Huiqing Li
Huiqing Li
Wen Kong
Wen Kong
Juan Zheng
Juan Zheng
Yan Li
Qi Wei
Qin Li
Li Yang
Ying Xu
Li Li
Hanyu Wang
Hanyu Wang
Hui Sun
Hui Sun
Wenfang Xia
Wenfang Xia
Geng Liu
Geng Liu
Xueyu Zhong
Xueyu Zhong
Kangli Qiu
Kangli Qiu
Han Wang
Han Wang
Hua Liu
Hua Liu
Xiaoli Song
Xiaoli Song
Si Xiong
Yumei Liu
Zhenhai Cui
Zhenhai Cui
Lulu Chen
Lulu Chen
Tianshu Zeng
Tianshu Zeng
Prognostic Value of Leucocyte to High-Density Lipoprotein-Cholesterol Ratios in COVID-19 Patients and the Diabetes Subgroup
Frontiers in Endocrinology
cohort study
coronavirus
COVID-19
neutrophil to high-density lipoprotein-cholesterol
high-density lipoprotein-cholesterol
prognosis
author_facet Yuxiu Wang
Yuxiu Wang
Jiaoyue Zhang
Jiaoyue Zhang
Huiqing Li
Huiqing Li
Wen Kong
Wen Kong
Juan Zheng
Juan Zheng
Yan Li
Qi Wei
Qin Li
Li Yang
Ying Xu
Li Li
Hanyu Wang
Hanyu Wang
Hui Sun
Hui Sun
Wenfang Xia
Wenfang Xia
Geng Liu
Geng Liu
Xueyu Zhong
Xueyu Zhong
Kangli Qiu
Kangli Qiu
Han Wang
Han Wang
Hua Liu
Hua Liu
Xiaoli Song
Xiaoli Song
Si Xiong
Yumei Liu
Zhenhai Cui
Zhenhai Cui
Lulu Chen
Lulu Chen
Tianshu Zeng
Tianshu Zeng
author_sort Yuxiu Wang
title Prognostic Value of Leucocyte to High-Density Lipoprotein-Cholesterol Ratios in COVID-19 Patients and the Diabetes Subgroup
title_short Prognostic Value of Leucocyte to High-Density Lipoprotein-Cholesterol Ratios in COVID-19 Patients and the Diabetes Subgroup
title_full Prognostic Value of Leucocyte to High-Density Lipoprotein-Cholesterol Ratios in COVID-19 Patients and the Diabetes Subgroup
title_fullStr Prognostic Value of Leucocyte to High-Density Lipoprotein-Cholesterol Ratios in COVID-19 Patients and the Diabetes Subgroup
title_full_unstemmed Prognostic Value of Leucocyte to High-Density Lipoprotein-Cholesterol Ratios in COVID-19 Patients and the Diabetes Subgroup
title_sort prognostic value of leucocyte to high-density lipoprotein-cholesterol ratios in covid-19 patients and the diabetes subgroup
publisher Frontiers Media S.A.
series Frontiers in Endocrinology
issn 1664-2392
publishDate 2021-09-01
description BackgroundBlood parameters, such as neutrophil-to-lymphocyte ratio, have been identified as reliable inflammatory markers with diagnostic and predictive value for the coronavirus disease 2019 (COVID-19). However, novel hematological parameters derived from high-density lipoprotein-cholesterol (HDL-C) have rarely been studied as indicators for the risk of poor outcomes in patients with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection. Here, we aimed to assess the prognostic value of these novel biomarkers in COVID-19 patients and the diabetes subgroup.MethodsWe conducted a multicenter retrospective cohort study involving all hospitalized patients with COVID-19 from January to March 2020 in five hospitals in Wuhan, China. Demographics, clinical and laboratory findings, and outcomes were recorded. Neutrophil to HDL-C ratio (NHR), monocyte to HDL-C ratio (MHR), lymphocyte to HDL-C ratio (LHR), and platelet to HDL-C ratio (PHR) were investigated and compared in both the overall population and the subgroup with diabetes. The associations between blood parameters at admission with primary composite end-point events (including mechanical ventilation, admission to the intensive care unit, or death) were analyzed using Cox proportional hazards regression models. Receiver operating characteristic curves were used to compare the utility of different blood parameters.ResultsOf 440 patients with COVID-19, 67 (15.2%) were critically ill. On admission, HDL-C concentration was decreased while NHR was high in patients with critical compared with non-critical COVID-19, and were independently associated with poor outcome as continuous variables in the overall population (HR: 0.213, 95% CI 0.090–0.507; HR: 1.066, 95% CI 1.030–1.103, respectively) after adjusting for confounding factors. Additionally, when HDL-C and NHR were examined as categorical variables, the HRs and 95% CIs for tertile 3 vs. tertile 1 were 0.280 (0.128–0.612) and 4.458 (1.817–10.938), respectively. Similar results were observed in the diabetes subgroup. ROC curves showed that the NHR had good performance in predicting worse outcomes. The cutoff point of the NHR was 5.50. However, the data in our present study could not confirm the possible predictive effect of LHR, MHR, and PHR on COVID-19 severity.ConclusionLower HDL-C concentrations and higher NHR at admission were observed in patients with critical COVID-19 than in those with noncritical COVID-19, and were significantly associated with a poor prognosis in COVID-19 patients as well as in the diabetes subgroup.
topic cohort study
coronavirus
COVID-19
neutrophil to high-density lipoprotein-cholesterol
high-density lipoprotein-cholesterol
prognosis
url https://www.frontiersin.org/articles/10.3389/fendo.2021.727419/full
work_keys_str_mv AT yuxiuwang prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT yuxiuwang prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT jiaoyuezhang prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT jiaoyuezhang prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT huiqingli prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT huiqingli prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT wenkong prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT wenkong prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT juanzheng prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT juanzheng prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT yanli prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT qiwei prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT qinli prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT liyang prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT yingxu prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT lili prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT hanyuwang prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT hanyuwang prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT huisun prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT huisun prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT wenfangxia prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT wenfangxia prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT gengliu prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT gengliu prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT xueyuzhong prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT xueyuzhong prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT kangliqiu prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT kangliqiu prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT hanwang prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT hanwang prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT hualiu prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT hualiu prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT xiaolisong prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT xiaolisong prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT sixiong prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT yumeiliu prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT zhenhaicui prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT zhenhaicui prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT luluchen prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT luluchen prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT tianshuzeng prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
AT tianshuzeng prognosticvalueofleucocytetohighdensitylipoproteincholesterolratiosincovid19patientsandthediabetessubgroup
_version_ 1717381399010344960
spelling doaj-1429f2d6136f433b88ad7a04628004152021-09-13T05:38:14ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-09-011210.3389/fendo.2021.727419727419Prognostic Value of Leucocyte to High-Density Lipoprotein-Cholesterol Ratios in COVID-19 Patients and the Diabetes SubgroupYuxiu Wang0Yuxiu Wang1Jiaoyue Zhang2Jiaoyue Zhang3Huiqing Li4Huiqing Li5Wen Kong6Wen Kong7Juan Zheng8Juan Zheng9Yan Li10Qi Wei11Qin Li12Li Yang13Ying Xu14Li Li15Hanyu Wang16Hanyu Wang17Hui Sun18Hui Sun19Wenfang Xia20Wenfang Xia21Geng Liu22Geng Liu23Xueyu Zhong24Xueyu Zhong25Kangli Qiu26Kangli Qiu27Han Wang28Han Wang29Hua Liu30Hua Liu31Xiaoli Song32Xiaoli Song33Si Xiong34Yumei Liu35Zhenhai Cui36Zhenhai Cui37Lulu Chen38Lulu Chen39Tianshu Zeng40Tianshu Zeng41Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Wuhan Wuchang Hospital, Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, ChinaDepartment of Endocrinology, Red Cross Hospital of Wuhan City, Wuhan, ChinaDepartment of Endocrinology, General Hospital of the Yangtze River Shipping, Wuhan, ChinaDepartment of Endocrinology, Hankou Hospital of Wuhan City, Wuhan, ChinaDepartment of Endocrinology, The Fifth Hospital of Wuhan, Wuhan, ChinaDepartment of Endocrinology, Wuhan Wuchang Hospital, Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, The Fifth Hospital of Wuhan, Wuhan, ChinaDepartment of Endocrinology, Hankou Hospital of Wuhan City, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, ChinaBackgroundBlood parameters, such as neutrophil-to-lymphocyte ratio, have been identified as reliable inflammatory markers with diagnostic and predictive value for the coronavirus disease 2019 (COVID-19). However, novel hematological parameters derived from high-density lipoprotein-cholesterol (HDL-C) have rarely been studied as indicators for the risk of poor outcomes in patients with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection. Here, we aimed to assess the prognostic value of these novel biomarkers in COVID-19 patients and the diabetes subgroup.MethodsWe conducted a multicenter retrospective cohort study involving all hospitalized patients with COVID-19 from January to March 2020 in five hospitals in Wuhan, China. Demographics, clinical and laboratory findings, and outcomes were recorded. Neutrophil to HDL-C ratio (NHR), monocyte to HDL-C ratio (MHR), lymphocyte to HDL-C ratio (LHR), and platelet to HDL-C ratio (PHR) were investigated and compared in both the overall population and the subgroup with diabetes. The associations between blood parameters at admission with primary composite end-point events (including mechanical ventilation, admission to the intensive care unit, or death) were analyzed using Cox proportional hazards regression models. Receiver operating characteristic curves were used to compare the utility of different blood parameters.ResultsOf 440 patients with COVID-19, 67 (15.2%) were critically ill. On admission, HDL-C concentration was decreased while NHR was high in patients with critical compared with non-critical COVID-19, and were independently associated with poor outcome as continuous variables in the overall population (HR: 0.213, 95% CI 0.090–0.507; HR: 1.066, 95% CI 1.030–1.103, respectively) after adjusting for confounding factors. Additionally, when HDL-C and NHR were examined as categorical variables, the HRs and 95% CIs for tertile 3 vs. tertile 1 were 0.280 (0.128–0.612) and 4.458 (1.817–10.938), respectively. Similar results were observed in the diabetes subgroup. ROC curves showed that the NHR had good performance in predicting worse outcomes. The cutoff point of the NHR was 5.50. However, the data in our present study could not confirm the possible predictive effect of LHR, MHR, and PHR on COVID-19 severity.ConclusionLower HDL-C concentrations and higher NHR at admission were observed in patients with critical COVID-19 than in those with noncritical COVID-19, and were significantly associated with a poor prognosis in COVID-19 patients as well as in the diabetes subgroup.https://www.frontiersin.org/articles/10.3389/fendo.2021.727419/fullcohort studycoronavirusCOVID-19neutrophil to high-density lipoprotein-cholesterolhigh-density lipoprotein-cholesterolprognosis